Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Contrave is available as an extended-release oral tablet, while Wegovy is available as a weekly subcutaneous injection
*Correspondence: Jana Frahm, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Serious Risks Both medications carry similar serious but rare risks: Pancreatitis: Can occur with either medication
As a drug pricing negotiation period is set for 60 days, the two sides had to complete the talks by the end of this month
To date, Phase 3 clinical trial data have also shown significant weight-loss outcomes, including up to 28.7% average body weight loss at 68 weeks in one obesity trial and 16.8% average weight loss at 40 weeks in adults with type 2 diabetes, with additional Phase 3 readouts still expected throughout 2026
The Access Landscape in Europe There are ~76M non-diabetic obese or overweight patients in EU4+UK countries [28]
